Home » Event agenda » Agenda – RWE, Market Access, Pricing & Reimbursement

10th RWE, Market Access, Pricing & Reimbursement 2023 Americas

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

30th November 1st December 2023, Philadelphia, USA


In the competitive world of pharmaceutical and medical technology, market access represents the process of understanding the implications
and the impact of a product in the healthcare market where a positive environment and communicating the ‘value’ of your product to the range
of customers who influence uptake will make a big difference.
Only a fully integrated organization can implement the processes, techniques, and strategies required to get the right messages to the right
stakeholders at the right time.
The U.S. pharma market is the largest pharmaceutical market worldwide and continues to grow even though there are expected structural
changes in the healthcare system due to evolving political landscape.
The two-day Market Access, Pricing, and Reimbursement Global Congress 2023 Americas will provide a unique platform and a dynamic
approach to key trends, methodologies, and insights on market access, real-world data, pricing, reimbursement, patient access, and data
collection than the current industry standard is anticipated.

The upcoming 2023 Market Access, Pricing, and Reimbursement Global Americas will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing, and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “A New Model of Access Strategy for the Next Normal.”. We are gathering together high-caliber expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the MAPR 2023 congress!

Sincerely yours,

Paradigm Global Events Team

Gain the latest insights on:

  • Strategies for one of the pharma industry’s greatest
    challenge: market access
  • Health Technology Assessment in Health-Care
  • Real world evidence and randomized control trials, close
    the gap
  • Growth of biosimilars and importance of RWE for orphan
    drugs and rare diseases
  • Emerging markets: the impact on global pricing and
  • Challenges and opportunities in pricing, reimbursement
    and patient access
  • Risk-sharing agreements, benefits, and challenges
  • Looking to the future: what is there to expect?

Who will you meet? 

Network with members of the boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

  • Market Access
  • Pricing and Reimbursement
  • Patient Outcomes
  • Health Economics and Outcomes Research
  • Payer Relations/ Evidence
  • Data Management/ Analysis
  • Regulatory Affairs
  • Public/ Government Affairs
  • Payers, HTA Officials, and Physicians
  • Business Development
  • Marketing
  • Commercial Executives
  • Product Launch
  • Real-world Evidence
  • Commercialization
  • Value Strategy
  • Product Strategy
  • Forecaster
  • Finance Officer

11th RWE, Market Access, Pricing & Reimbursement 2024 Americas

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

Day 1 - Monday 9th September 2024


  • Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution
  • Keeping on top of pricing and market access trends
  • Identify a clinical or economic advantage and generate the appropriate clinical and health
    economic evidence to support a strong value proposition
  • The importance of Patient-Reported Outcomes
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Understanding the intricate regulatory landscape
  • Navigating complex requirements to achieve and maintain market access in the US and around the world
  • Practical approaches and strategic planning
  • Best practices
  • Benefits of understanding differences across stakeholders
  • Multiple stakeholder approach to planning and delivering evidence is required
    A dedicated strategy to meet their specific evidence needs
    Determine whether a multiple stakeholder approach is justified.
  • New landscape for risk-sharing agreements among manufacturer, payer and patients
  • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
  • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
  • Addressing the factors that made the launch environment more challenging
  • Capabilities needed for an effective drug launch
  • How to best leverage outsourced partners to achieve success.
  • Best practices to achieve successful commercialisation.


  • Recent advances in digital and advanced analytics for RWE generation
  • What role can it play across the pharma value chain?
  • What are the important aspects involved in utilising RWE to support product effectiveness?
  • How can this be used to advance reimbursement model?
  • Major factors contributing to the pharmaceutical industry’s excitement about RWE
  • Addressing the challenges of collecting and consolidating RWD data that can be put to good use.
  • Important role of RWE clinical trials
  • Real-world data and evidence as a more integral part of the drug development process.

Jason Noto, Senior Vice President, US Market Access, AVEO Oncology

  • How is RWD and RWE bringing innovation to patients and gaining approval
  • Importance of RWD in transforming clinical research and clinical trial design
  • Experiences to date and identify practical and technological considerations to further implement real-world clinical research
  • The use of RWD early in the process to boost trial diversity and inclusion
  • Challenge in setting diversity goals early in clinical trial planning
  • Development of a diversity plan to ensure adequate representation of racial and ethnic
    subgroups in clinical trials
  • Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post-marketing requirements or commitments for safety and efficacy data in a diverse patient population
  • Why is RWE increasingly being recognised and acknowledged as an evolution in product research and development.
  • How does RWE help regulators, pharmaceutical companies and clinicians better identify trends and patterns in patient outcomes
  • Understanding the risks & opportunities to both payer and industry
  • How does real-world evidence help ensure market access?
  • It’s use in supporting a robust post market surveillance and accelerating products to market

11th Market Access, Pricing & Reimbursement 2024 Americas

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

Day 2 - Tuesday 10th September 2024


  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship
  • Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
  • Key principles that ensure access to treatment based on need
  • Patient-centeredness, patient advocacy
  • Access to innovative medicines remains a key issue worldwide
  • Limitations of the some of the initiatives to address this
  • How can pharmaceutical companies and health authorities work together to bridge the gap
  • How the pharmaceutical industry will need to navigate the potential access challenges in the
  • US associated with the Inflation Reduction Act and Medicare having the authority to negotiate drug prices
  • Summary of CMS’s proposed approach to measuring value and determining a maximum fair price
  • Highlight innovative policy options that CMS should consider for robust Medicare drug price negotiations
  • Lessons learned from negotiating drug prices with governments outside of the US.

Danielle Bargo, Director, Real World Evidence and HEOR, Eisai

  • Why is this important?
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing
  • Effective communications with internal and external stakeholders
  • Importance of stakeholder collaboration
  • Understanding the benefits of a good collaboration between payers and pharma to ensure appropriate patient access
  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations
  • The increasing relevance of Emerging Markets
  • EMs Embrace Technological Innovation
  • Creating value through partnership
  • How to Avoid the Pitfalls of Innovation in Emerging Markets
  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success
  • Assessment of financial benefit from tendering
  • Evaluating its impact on prices and market concentration
  • Consideration of its operational framework
  • Tendering for pharmaceuticals as a reimbursement tool
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between countries
  • Frontiers in Health Care
  • What will the future bring?
Scroll to Top